Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad, sunitinib has on
patients and their tumors. At this time, no drugs are routinely used to treat meningioma,
hemangioblastoma or hemangiopericytoma. Only surgery and radiation therapy are known to be
useful.
Sunitinib is a drug approved for advanced kidney cancer. Sunitinib is also being studied for
other tumors. It may be useful in the treatment of brain tumors because it can prevent
formation of new blood vessels that allow tumor cells to survive and grow.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Dana-Farber Cancer Institute Pfizer University of Pittsburgh University of Virginia